Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 5/20 | 0.46 |
| ▸ | TRPV1 | Q8NER1 | 7/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | FLT1 | P17948 | 3/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1941875 | 0.92 | KMT2A (0.49) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL3924809 | 0.92 | KDR (0.51) | KMT2AKDRTRPV1 | |
| SCHEMBL3935683 | 0.89 | KDR (0.59) | KMT2AKDRNPC1TSHR | |
| SCHEMBL3927552 | 0.88 | KMT2A (0.45) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL3924135 | 0.87 | KMT2A (0.46) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL3935938 | 0.86 | KMT2A (0.44) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL3928466 | 0.85 | KMT2A (0.47) | KMT2AKDRNPC1 | |
| SCHEMBL3926494 | 0.85 | KDR (0.54) | KMT2AKDRTRPV1NAMPTFLT1 | |
| SCHEMBL1941141 | 0.84 | TDP1 (0.44) | KMT2AKDRTRPV1 | |
| SCHEMBL3935235 | 0.84 | KDR (0.45) | KMT2AKDRNPC1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7544703-B2 | Cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2009-06-09 | — | — | US | disclosed |
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149574-A1 | Novel cyclic compound having 4-pyridylalkylthio group having substituted or unsubstituted amino group introduced therein | FLT4, FLT1, TIE1 | KMT2A 2966/4885KDR 12/4885TRPV1 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.